Clinical effectiveness of brinzolamide 1%–brimonidine 0.2% fixed combination for primary open-angle glaucoma and ocular hypertension

References

• WebersCABeckersHJNuijtsRMSchoutenJSPharmacological management of primary open-angle glaucoma: second-line options and beyondDrugs Aging20082572975918729546
   PubMed Web of Science ®Google Scholar
• BogerWP3rdShortterm “escape” and longterm “drift”. The dissipation effects of the beta adrenergic blocking agentsSurv Ophthalmol198328Suppl2352426141645
   PubMedGoogle Scholar
• QuigleyHAEngerCKatzJSommerAScottRGilbertDRisk factors for the development of glaucomatous visual field loss in ocular hypertensionArch Ophthalmol19941126446498185522
   PubMed Web of Science ®Google Scholar
• KassMAHeuerDKHigginbothamEJThe Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucomaArch Ophthalmol200212070171312049574
   PubMed Web of Science ®Google Scholar
• BarnebeyHOrengo-NaniaSFlowersBEThe safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solutionAm J Ophthalmol20051401715990081
   PubMed Web of Science ®Google Scholar
• LeeAJMcCluskeyPFixed combination of topical brimonidine 0.2% and timolol 0.5% for glaucoma and uncontrolled intraocular pressureClin Ophthalmol2008254555519668752
   PubMedGoogle Scholar
• InoueKShiokawaMSugaharaMWakakuraMSoedaSTomitaGThree-month evaluation of dorzolamide hydrochloride/timolol maleate fixed-combination eye drops versus the separate use of both drugsJpn J Ophthalmol20125655956323001284
   PubMed Web of Science ®Google Scholar
• HigginbothamEJHansenJDavisEJWaltJGGuckianAGlaucoma medication persistence with a fixed combination versus multiple bottlesCurr Med Res Opin2009252543254719731993
   PubMed Web of Science ®Google Scholar
• TaniguchiTKitazawaYThe potential systemic effect of topically applied β-blockers in glaucoma therapyCurr Opin Ophthalmol19978555810168358
   PubMedGoogle Scholar
• US Food Drug AdministrationFDA approves Simbrinza for glaucoma, ocular hypertension2013 Available from: http://www.medscape.com/viewarticle/803064Accessed April 18, 2015
   Google Scholar
• CvetkovicRSPerryCMBrinzolamide: a review of its use in the management of primary open-angle glaucoma and ocular hypertensionDrugs Aging20032091994714565787
   PubMed Web of Science ®Google Scholar
• European Glaucoma SocietyTerminology and Guidelines for Glaucoma3rd edSavona, ItalyEditrice Dogma SRL2008
   Google Scholar
• AdkinsJCBalfourJABrimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertensionDrugs Aging1998122252419534022
   PubMed Web of Science ®Google Scholar
• KrupinTLiebmannJMGreenfieldDSRitchRGardinerSA randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment studyAm J Ophthalmol201115167168121257146
   PubMed Web of Science ®Google Scholar
• WangTHHuangJYHungPTShiehJWChenYFOcular hypotensive effect and safety of brinzolamide ophthalmic solution in open angle glaucoma patientsJ Formos Med Assoc200410336937315216404
   PubMed Web of Science ®Google Scholar
• IesterMBrinzolamide ophthalmic suspension: a review of its pharmacology and use in the treatment of open angle glaucoma and ocular hypertensionClin Ophthalmol2008251752319668749
   PubMedGoogle Scholar
• van der ValkRWebersCASchoutenJSZeegersMPHendrikseFPrinsMHIntraocular pressure-lowering effects of all commonly used glaucoma drugs. A meta-analysis of randomized clinical trialsOphthalmology20051121177118515921747
   PubMed Web of Science ®Google Scholar
• MelamedSDavidROngoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results. Brimonidine Study Group IIClin Ther20002210311110688394
   PubMed Web of Science ®Google Scholar
• TorisCCamrasCYablonskiMAcute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patientsAm J Ophthalmol199912881410482088
   PubMed Web of Science ®Google Scholar
• Centre for Drug Evaluation and ResearchClinical pharmacology and biopharmaceutics review(s)2013 Available from: www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204251Orig1s000ClinPharmR.pdfAccessed October 18, 2015
   Google Scholar
• Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2% [package insert]Fort Worth, TXAlcon Laboratories Inc2013
   Google Scholar
• FellmanRLSullivanEKRatliffMComparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trialOphthalmology2002109998100811986110
   PubMed Web of Science ®Google Scholar
• NguyenQHMcMenemyMGRealiniTWhitsonJTGoodeSMPhase 3 randomized 3-month trial with an ongoing 3-month safety extension of fixed-combination brinzolamide 1%/brimonidine 0.2%J Ocul Pharmacol Ther20132929029723425430
   PubMed Web of Science ®Google Scholar
• WhitsonJTRealiniTNguyenQHMcMenemyMGGoodeSMSix-month results from a phase III randomized trial of fixed-combination brinzolamide 1% + brimonidine 0.2% versus brinzolamide or brimonidine monotherapy in glaucoma or ocular hypertensionClin Ophthalmol201371053106023766627
   PubMedGoogle Scholar
• KatzGDubinerHSamplesJVoldSSallKThree month randomized trial of fixed combination brinzolamide, 1%, and brimonidine, 0.2%JAMA Ophthalmol201313172473023579344
   PubMed Web of Science ®Google Scholar
• RealiniTNguyenQHKatzGDubinerHFixed-combination brinzolamide 1%/brimonidine 0.2% vs monotherapy with brinzolamide or brimonidine in patients with open-angle glaucoma or ocular hypertension: results of a pooled analysis of two phase 3 studiesEye (Lond)20132784184723640612
   PubMed Web of Science ®Google Scholar
• AungTLaganovskaGHernandez ParedesTJBranchJDTsorbatzoglouAGoldbergITwice-daily brinzolamide/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertensionOphthalmology20141212348235525064721
   PubMed Web of Science ®Google Scholar
• GandolfiSALimJSanseauACParra RestrepoJCHamacherTRandomized trial of brinzolamide/brimonidine versus brinzolamide plus brimonidine for open-angle glaucoma or ocular hypertensionAdv Ther2014311213122725430900
   PubMed Web of Science ®Google Scholar
• EnyediLBFreedmanSFSafety and efficacy of brimonidine in children with glaucomaJ AAPOS2001528128411641636
   PubMed Web of Science ®Google Scholar
• TepedinoMComparison of combigan BID versus simbrinza TID Available from: https://clinicaltrials.gov/ct2/show/NCT02167035. NLM identifier NCT02167035Accessed April 18, 2015
   Google Scholar
• SkalickySEGoldbergIMcCluskeyPOcular surface disease and quality of life in patients with glaucomaAm J Ophthalmol201215319.e221872203
   PubMed Web of Science ®Google Scholar
• RossiGCPasinettiGMScudellerLRaimondiMLanteriSBianchiPERisk factors to develop ocular surface disease in treated glaucoma or ocular hypertension patientsEur J Ophthalmol20132329630223335308
   PubMed Web of Science ®Google Scholar
• CantorLBBrimonidine in the treatment of glaucoma and ocular hypertensionTher Clin Risk Manag2006233734618360646
   PubMedGoogle Scholar
• GoldbergIGil PinaRLanzagorta-ArestiASchiffmanRMLiuCBejanianMBimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomized controlled trialBr J Ophthalmol20149892693124667994
   PubMed Web of Science ®Google Scholar
• HollóGHommerAAntón LópezARopoAEfficacy, safety, and tolerability of preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5% versus concomitant use of the ingredientsJ Ocul Pharmacol Ther20143046847524738883
   PubMed Web of Science ®Google Scholar
• GandolfiSParedesTGoldbergIComparison of a travoprost BAK-free formulation preserved with polyquaternium-1 with BAK-preserved travoprost in ocular hypertension or open-angle glaucomaEur J Ophthalmol201222344422167541
   PubMed Web of Science ®Google Scholar
• ReardonGKotakSSchwartzGFObjective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic reviewPatient Prefer Adherence2011544146322003282
   PubMed Web of Science ®Google Scholar
• OlthoffCMSchoutenJSvan de BorneBWWebersCANoncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension: an evidence-based reviewOphthalmology200511295396115885795
   PubMed Web of Science ®Google Scholar
• OsterbergLBlaschkeTAdherence to medicationN Engl J Med200535348749716079372
   PubMed Web of Science ®Google Scholar
• RossiGCPasinettiGMScudellerLTinelliCMilanoGBianchiPEMonitoring adherence rates in glaucoma patients using the Travatan dosing aid. A 6-month study comparing patients on travoprost 0.004% and patients on travoprost 0.004%/timolol 0.5% fixed combinationExpert Opin Pharmacother20101149950420163264
   PubMed Web of Science ®Google Scholar
• SleathBRobinALCovertDByrdJETudorGSvarstadBPatient-reported behavior and problems in using glaucoma medicationsOphthalmology200611343143616458967
   PubMed Web of Science ®Google Scholar
• DjafariFLeskMRHarasymowyczPJDesjardinsDLachaineJDeterminants of adherence to glaucoma medical therapy in a long-term patient populationJ Glaucoma20091823824319295380
   PubMed Web of Science ®Google Scholar
• TaylorSAGalbraithSMMillsRPCauses of non-compliance with drug regimens in glaucoma patients: a qualitative studyJ Ocul Pharmacol Ther20021840140912419091
   PubMed Web of Science ®Google Scholar
• RobinALNovackGDCovertDWCrockettRSMarcicTSAdherence in glaucoma: objective measurements of once-daily and adjunctive medication useAm J Ophthalmol200714453354017686450
   PubMed Web of Science ®Google Scholar
• GurwitzJHGlynnRJMonaneMTreatment for glaucoma: adherence by the elderlyAm J Public Health1993837117168484454
   PubMed Web of Science ®Google Scholar
• RotchfordAPMurphyKMCompliance with timolol treatment in glaucomaEye (Lond)1998122342369683946
   PubMed Web of Science ®Google Scholar
• FlowersBWandMPiltz-SeymourJPatients’ and physicians’ perceptions of the travoprost dosing aid: an open-label, multicenter study of adherence with prostaglandin analogue therapy for open-angle glaucoma or ocular hypertensionClin Ther2006281803181117213000
   PubMed Web of Science ®Google Scholar